Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG KWIKPEN versus NOVOLIN 70 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG KWIKPEN versus NOVOLIN 70 30.
HUMALOG KWIKPEN vs NOVOLIN 70/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production.
Novolin 70/30 is a biphasic insulin analog consisting of 70% insulin aspart protamine suspension (intermediate-acting) and 30% insulin aspart (rapid-acting). It lowers blood glucose by promoting peripheral glucose uptake, inhibiting hepatic gluconeogenesis, and suppressing lipolysis and proteolysis.
Subcutaneous injection: individualize dose; typical total daily dose 0.5-1 unit/kg; rapid-acting insulin given 0-15 minutes before or immediately after meals.
Subcutaneous injection, 0.5-1 unit/kg/day divided into 2-3 doses, typically before meals and at bedtime; adjust based on blood glucose monitoring.
None Documented
None Documented
Terminal elimination half-life: approximately 26 minutes (range 0.6-1.2 hours in some studies) following subcutaneous administration, reflecting rapid clearance from the systemic circulation.
Terminal half-life for NPH component is approximately 13 hours; regular insulin component half-life is 5-6 hours. Clinical context: Provides basal coverage for 18-24 hours.
Renal: 60-80% of insulin lispro is metabolized primarily in the liver and kidneys, with metabolites and a small amount of intact drug excreted in urine.
Renal: 30-80% of administered insulin is excreted via kidneys; remainder is metabolized in liver and muscle. Biliary/fecal excretion is negligible.
Category C
Category C
Insulin
Insulin